Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
Black Diamond Therapeutics (BDTX) Stock Price & Analysis
560 Followers
BDTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.18 - $4.08
Previous Close$1.82
Volume63.99K
Average Volume (3M)151.42K
Market Cap
$66.40M
Enterprise Value-$28.27M
Total Cash (Recent Filing)$122.81M
Total Debt (Recent Filing)$28.14M
Price to Earnings (P/E)-0.7
Beta2.11
Next Earnings
May 16, 2023EPS Estimate
-$0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.51
Shares Outstanding36,481,146
10 Day Avg. Volume153,032
30 Day Avg. Volume151,424
Standard Deviation0.26
R-Squared0.19
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$9.00Price Target Upside394.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Black Diamond Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BDTX FAQ
What was Black Diamond Therapeutics’s price range in the past 12 months?
Black Diamond Therapeutics lowest stock price was $1.18 and its highest was $4.08 in the past 12 months.
What is Black Diamond Therapeutics’s market cap?
Currently, no data Available
When is Black Diamond Therapeutics’s upcoming earnings report date?
Black Diamond Therapeutics’s upcoming earnings report date is May 16, 2023 which is in 51 days.
How were Black Diamond Therapeutics’s earnings last quarter?
Black Diamond Therapeutics released its earnings results on Mar 09, 2023. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.627 by $0.037.
Is Black Diamond Therapeutics overvalued?
According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued.
Does Black Diamond Therapeutics pay dividends?
Black Diamond Therapeutics does not currently pay dividends.
What is Black Diamond Therapeutics’s EPS estimate?
Black Diamond Therapeutics’s EPS estimate is -$0.61.
How many shares outstanding does Black Diamond Therapeutics have?
Black Diamond Therapeutics has 36,481,148 shares outstanding.
What happened to Black Diamond Therapeutics’s price movement after its last earnings report?
Black Diamond Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.627. Following the earnings report the stock price went down -13.69%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics?
Among the largest hedge funds holding Black Diamond Therapeutics’s share is RA Capital Management. It holds Black Diamond Therapeutics’s shares valued at 5M.
---
Black Diamond Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (394.51% Upside)
$9.00 (394.51% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.47%
12-Months-Change
Fundamentals
Return on Equity
-58.52%
Trailing 12-Months
Asset Growth
-36.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding BDTX
Fidelity Nasdaq Composite Index ETF
$223.94K
Up to five ETFs with an Outperform Smart Score that hold BDTX. The ETFs are listed according to market value of BDTX within the ETF
---
---